Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
2005-08-30
2005-08-30
Nazario-Gonzalez, Porfirio (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
C556S136000, C556S137000
Reexamination Certificate
active
06936634
ABSTRACT:
Compounds which may be used in the treatment and/or prevention of cancer have the formula (I): wherein R1and R2together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic group
REFERENCES:
patent: 4699978 (1987-10-01), Barton
patent: 4843069 (1989-06-01), Keller et al.
patent: 4980472 (1990-12-01), Tomcufcik et al.
patent: 5225556 (1993-07-01), Barton
patent: 11209314 (1999-03-01), None
patent: WO 86/00804 (1986-02-01), None
patent: WO 96/13510 (1996-05-01), None
patent: WO 02/40494 (2002-05-01), None
Aird et al., “In vitro and in vivo activity and cross resistance profiles of novel ruthemium (II) . . . ” Brit. J. of Cancer 86:1652-1657, 2002.
Aird et al., “RM175, a novel ruthenium (RuII) organo-metallic complex: patterns of resistance . . . ” Brit. J. of Cancer 85 (suppl. 1):101, 2001.
Allardyce et al., “Ruthenium in Medicine: Current Clinical Uses and Future Prospects” Plat. Metals Rev. 45:62-69, 2001.
Allardyce et al., “[Ru(η6-p-cymene)Cl2(pta)] . . . a water soluble compound that exhibits pH dependent DNA binding . . . ” Chem. Commun. 15:1396-1397, 2001.
Aronson et al., “The reactions of Ru(η6-arene)Cl2l2compounds with a series of aminopyridine ligands: . . . ” Polyhedron 10:1727-1732, 1991.
Beasley et al., “Complexation of 1,4,5,8,9,10-Hexahydroanthracene (HHA) to iron or ruthenium . . . ” Organometallics 12:4599-4606, 1993.
Bennett et al., “Arene ruthenium (II) complexes formed by dehydrogenation of cyclohexadiences . . . ” J. Chem. Soc. 2:233-241, 1974.
Bennett et al., “Mono-and bis-(acetylacetonato) complexes of arene-ruthenium (II) and arene-osmium (II): . . . ” J. Chem. 70:6555-660, 2001.
Carmona et al., “Synthesis, X-Ray Structure and Nuclear Magnetic Resonance . . . ” J. Chem. Soc. Dalton Trans. 1463-1476, 1990.
Chen et al., “Organometallic ruthenium (II) Diamine anticancer complexes: . . . ” J. Am. Chem. Soc. 124:3064-3082, 2002.
Cetinkaya et al., “Antibacterial and antifungal activities of complexes of ruthenium (II)” Arnzeim.-Forsch. 49:538-540, 1999.
Crabtree et al., “Arene-Ruthenium Complexes Containing Nitrogen Donor Ligands” J. of Organometallic Chem. 141:325-330, 1977.
Cummings et al., “Novel ruthenium (RuII) organo-metallic complexes: in vitro cytotoxicity . . . ” Clinical Cancer Research 6 (suppl. 4494s) 2000.
Elsegood et al, “The synthesis of new paracyclophane complexes of ruthenium (II): . . . ” J. of Organometallic Chem 356:C29-C31, 1988.
Garcia et al., “Reactivity of [{(η6-arene)RuCl(μ-Cl)}2] towards some potentially bidentate ligands . . . ” J. of Organometallic Chem. 467:119-126, 1994.
Gleichmann et al., “η3-Pentamethylcyclopentadienylruthenium (II) complexes containing . . . ” J. Chem. Soc. Dalton Trans. 1549-1554, 1995.
Gupta et al., “Synthesis, characterization, reactivity and structure of some mono and binuclear . . . ” J. of Organometallic Chem. 568:13-20, 1998.
Hung et al., “Aquo Chemistry of Monoarene Complexes of Osmiium (II) and Ruthenium(II)” Inorganic Chem 20 457-463, 1981.
Jensen et al., “Facile preparation of η6-p-cymene ruthenium diphosphine complexes.” J. of Organometallic Chem. 556:151-158, 1998.
Korn et al., “Oligometic (n6-arene) ruthenium (II) complexes of adenine and adenosime with N6; N7 coordination” Inorganica Chimica Acta 254:85-91, 1997.
Kramer, R., “Application of π-Arene-Ruthenium complexes in peptide labeling and peptide synthesis” Andew. Chem. Int. Ed. Engl. 35:1197-1199, 1996.
Morris et al., “Inhibition of cancer cell growth by ruthenium (II) arene complexes” J. Med. Chem. 44:3616-3621, 2001.
Muller et al., “(η6-Aren) (η4-buta-1,3-dien)ruthenium(0)-Komplexe: . . . ”J. of Organometallic Chem 458:219-224, 1993.
Pandey et al., “Synthesis and characterization of [Ru(η6-C6Me6)Cl2(CNPy)] and . . . ” Indian J. of Chemistry 35A:434-437, 1996.
Pathak et al., “Synthesis and characterization of [{Ru(η6-C6Me6)Cl2}2 (μ-DCBT)] and its reaction . . . ” Indian J. of Chem. 37A:165-168, 1998.
Pertici et al., “Synthesis of the Arene complex . . . ” J. Chem. Soc. Dalton Trans 315-319, 1988.
Sheldrick et al., “Synthesis and structural characterization of η6-arene-ruthenium (II) . . . ” J. of Organometallic Chem. 377:357-366, 1989.
Sheldrick et al., “η3-Pentamethycyclopentadienylruthenium (II) complexes containing . . . ” J. of Organometallic Chem. 470:183-187, 1994.
Sheldrick et al., “Synthesis and structural characterization of η6-Arene-ruthenium (II) complexes . . . ” Onorganica Chimica Acta. 168:93-100, 1990.
Solorzano et al., “Preparation of arene ruthenium (II) complexes with activated ligands for protein labeling” Inorganic Chim. Acta 97:135-141, 1985.
Wolff et al., “(η6-Arene)ruthenium(II) labeling of amino acids and peptides . . . ”Chemische Berichte-Recueil 130:981-988, 1997.
Wolff et al., “Bis(arene) ruthenium (II) complexes containing η6-coordinated phenylalanine derivatives” J. or Organometallic Chem. 531:141-149, 1997.
Zelonka et al., “Benzene complexes of ruthenium (II)” Canadian J. of Chem. 50:3063-3072, 1972.
Chen Haimei
Jodrell Duncan
Morris Robert Edward
Sadler Peter John
Fish & Richardson P.C.
Nazario-Gonzalez Porfirio
The University Court, The University of Edinburgh (UK)
LandOfFree
Ruthenium (II) compounds for use in the therapy of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ruthenium (II) compounds for use in the therapy of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ruthenium (II) compounds for use in the therapy of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501882